Clinical trial
A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis…
NCT00430495 · EMD Serono, Industry · Completed
Key facts
| NCT number | NCT00430495 |
|---|---|
| Title | A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I) |
| Official title | A Randomized, Double-blind, Placebo-controlled, Multicentre, Phase II Dose-finding Study of Atacicept Given Subcutaneously in Subjects With Rheumatoid Arthritis and Inadequate Response to TNFa Antagonist Therapy |
| Acronym | AUGUST I |
| Lead sponsor | EMD Serono, Industry |
| Collaborators | Merck KGaA, Darmstadt, Germany Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | Atacicept, Placebo matched to atacicept |
| Enrollment | 256 |
| Start date | Dec 1, 2006 |
| Primary completion | Sep 1, 2009 |
| Completion | Sep 1, 2009 |
| First posted | Feb 2, 2007 |
| Last update posted | Feb 17, 2016 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: